These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17075487)

  • 1. [Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Marcellin P; Lada O
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S5-8. PubMed ID: 17075487
    [No Abstract]   [Full Text] [Related]  

  • 2. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Bourlière M
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
    [No Abstract]   [Full Text] [Related]  

  • 3. [Managing resistance to analogue antiviral drugs in a chronic compensated hepatitis B patient].
    Bronowicki JP; Barraud H; Couzigou P
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S17-9. PubMed ID: 17075490
    [No Abstract]   [Full Text] [Related]  

  • 4. [Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
    Zarski JP
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S20-1. PubMed ID: 17075491
    [No Abstract]   [Full Text] [Related]  

  • 5. [Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Zoulim F
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S9-11. PubMed ID: 17075488
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
    Pariente A; Tachet A; Poveda JD
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1059-60. PubMed ID: 12483147
    [No Abstract]   [Full Text] [Related]  

  • 7. How to overcome antiviral-resistant hepatitis B virus?
    Song BC
    Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy.
    Kaplan DD; Reddy KR
    Am J Gastroenterol; 2002 Sep; 97(9):2465-7. PubMed ID: 12358276
    [No Abstract]   [Full Text] [Related]  

  • 10. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HBV mutations during antiviral therapy in patients with chronic hepatitis B].
    Hwang SG
    Korean J Hepatol; 2005 Dec; 11(4):311-9. PubMed ID: 16380660
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiviral therapy of chronic hepatitis B.
    Zoulim F
    Antiviral Res; 2006 Sep; 71(2-3):206-15. PubMed ID: 16716414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic hepatitis B: back to the future with HBsAg.
    Moucari R; Lada O; Marcellin P
    Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of chronic hepatitis B and the implications of viral resistance to therapy.
    Mauss S; Wedemeyer H
    Expert Rev Anti Infect Ther; 2008 Apr; 6(2):191-9. PubMed ID: 18380601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
    MMW Fortschr Med; 2009 May; 151(22):38-9. PubMed ID: 19526965
    [No Abstract]   [Full Text] [Related]  

  • 16. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
    Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
    J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical consequences of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Cadranel JF
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S12-6. PubMed ID: 17075489
    [No Abstract]   [Full Text] [Related]  

  • 18. Entecavir surprise.
    Hirsch MS
    N Engl J Med; 2007 Jun; 356(25):2641-3. PubMed ID: 17582076
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coevolution and HBV drug resistance.
    Khudyakov Y
    Antivir Ther; 2010; 15(3 Pt B):505-15. PubMed ID: 20516572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.